Search results for "Statin"

showing 10 items of 545 documents

Control of Gastric Acid Secretion in Somatostatin Receptor 2 Deficient Mice: Shift from Endocrine/Paracrine to Neurocrine Pathways

2007

The gastrin-enterochromaffin-like (ECL) cell-parietal cell axis is known to play an important role in the regulation of gastric acid secretion. Somatostatin, acting on somatostatin receptor type 2 (SSTR2), interferes with this axis by suppressing the activity of the gastrin cells, ECL cells, and parietal cells. Surprisingly, however, freely fed SSTR2 knockout mice seem to display normal circulating gastrin concentration and unchanged acid output. In the present study, we compared the control of acid secretion in these mutant mice with that in wild-type mice. In SSTR2 knockout mice, the number of gastrin cells was unchanged; whereas the numbers of somatostatin cells were reduced in the antru…

medicine.medical_specialtyendocrine systemCell CountGalaninBiologyHistidine DecarboxylaseArticleGastric AcidMiceEndocrinologyParietal Cells GastricInternal medicineParacrine CommunicationmedicineEnterochromaffin CellsSomatostatin receptor 2AnimalsReceptors SomatostatinEnterochromaffin-like cellGastrinMice KnockoutDelta cellSomatostatin receptorGastrin-Secreting Cellsdigestive oral and skin physiologyNeurosecretory SystemsMicroscopy ElectronEndocrinologySomatostatinGastric MucosaVesicular Monoamine Transport ProteinsG cellReceptors Galaninhormones hormone substitutes and hormone antagonists
researchProduct

Oncostatin M, leukaemia-inhibitory factor and interleukin 6 trigger different effects on alpha1-proteinase inhibitor synthesis in human lung-derived …

1998

Interleukin 6 (IL-6), oncostatin M (OSM) and leukaemia-inhibitory factor (LIF) share a common signal-transducing subunit in each of their receptors and thus mediate an overlapping spectrum of biological activities. Although all of these cytokines stimulate the production of α1-proteinase inhibitor (α1-PI) in hepatocyte-derived cells, only OSM is able to up-regulate levels of this inhibitor in epithelial cells originating from the lung. In this study we characterized human lung-derived epithelial-like HTB58 cells for their ability to synthesize α1-PI after treatment with IL-6, OSM and LIF. The results demonstrate that the resistance of HTB58 cells to the effects of IL-6 and LIF was not becau…

medicine.medical_specialtyendocrine systemProtein subunitBlotting WesternOncostatin MInhibitory postsynaptic potentialBiochemistryLeukemia Inhibitory FactorInternal medicinemedicineTumor Cells CulturedHumansInterleukin 6ReceptorMolecular BiologyLungLymphokinesbiologyChemistryInterleukin-6fungiOncostatin MOncostatin M receptorEpithelial CellsCell BiologyGlycoprotein 130Blotting NorthernGrowth InhibitorsCell biologyInterleukin 31Endocrinologyalpha 1-Antitrypsinbiology.proteinPeptidesResearch ArticleThe Biochemical journal
researchProduct

Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis

2018

AbstractWe conducted a systematic review and meta-analysis to investigate whether the use of statins could be associated with the risk of all-caused dementia, Alzheimer’s disease (AD), vascular dementia (VaD), and mild cognitive impairment (MCI). Major electronic databases were searched until December 27th, 2017 for studies investigating use of statins and incident cognitive decline in adults. Random-effects meta-analyses calculating relative risks (RRs) were conducted to synthesize effect sizes of individual studies. Twenty-five studies met eligibility criteria. Use of statins was significantly associated with a reduced risk of all-caused dementia (k = 16 studies, adjusted RR (aRR) = 0.849…

medicine.medical_specialtylcsh:MedicineSubgroup analysisRisk AssessmentArticle03 medical and health sciences0302 clinical medicinemild cognitive impairmentInternal medicineMedicineDementiaHumansCognitive Dysfunction030212 general & internal medicineCognitive declineProspective cohort studyVascular dementialcsh:ScienceMultidisciplinarybusiness.industrylcsh:RStatinInibidores de Hidroximetilglutaril-CoA Redutasesmedicine.diseaseRelative riskMeta-analysislcsh:QDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessment030217 neurology & neurosurgerydementiaDemência
researchProduct

111-Indium-DTPA-Octreotid-Szintigraphie bei kolorektalen Lebermetastasen

1997

The somatostatin analogue octreotide is effective in the treatment of neuroendocrine and other tumours. 111-In-labelled DTPA-octreotide scintigraphy is successful in localizing primary neuroendocrine tumours and metastases and other tumours containing somatostatin receptors. An antiproliferative effect of octreotide was also demonstrated for colorectal carcinoma. Since only about 40% of colorectal carcinomas express somatostatin receptors, we tried to establish whether 111-In-labelled DTPA-octreotide scintigraphy is able to reveal the receptor status of liver metastases in patients with colorectal liver metastases. This would be useful in selecting patients for adjuvant therapy studies with…

medicine.medical_specialtymedicine.diagnostic_testSomatostatin receptorbusiness.industryOctreotidemedicine.diseaseScintigraphyGastroenterologySomatostatinInternal medicineCarcinomamedicineAdjuvant therapyAdenocarcinomaSurgerybusinessmedicine.drugSomatostatin Receptor PositiveLangenbeck's Archives of Surgery
researchProduct

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involvin…

2013

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in…

medicine.medical_specialtymedicine.medical_treatmentDiseaseCochrane Librarylaw.inventionRandomized controlled triallawRenal DialysisInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicineDialysisRandomized Controlled Trials as TopicPharmacologybusiness.industrymedicine.diseaseConfidence intervalCardiovascular events Chronic kidney disease Dialysis Mortality Statins StrokeStrokeCardiovascular DiseasesMeta-analysisRelative riskHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessKidney diseasePharmacological research
researchProduct

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

2021

Introduction Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypo…

medicine.medical_specialtymedicine.medical_treatmentNesidioblastosisOctreotideCase ReportHypoglycemiaGastroenterologychemistry.chemical_compoundInternal medicinemedicineDiazoxidePharmacology (medical)business.industryInsulinnutritional and metabolic diseasesmedicine.diseasenesidioblastosisPasireotidediazoxideSomatostatinhypoglycemiachemistrySitagliptinpasireotide LARbusinessmedicine.drugClinical Pharmacology : Advances and Applications
researchProduct

Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration

2018

PurposeThe ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice.ParticipantsTRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definiti…

medicine.medical_treatment2700 General Medicineregistry030204 cardiovascular system & hematologyRECOMMENDATIONS3124 Neurology and psychiatryBrain Ischemia0302 clinical medicineMedicineProspective StudiesRegistries10064 Neuroscience Center ZurichProspective cohort studyIntersectoral CollaborationThrombectomyRISKEndovascular ProceduresThrombolysisGeneral Medicine3. Good healthStrokeCohortrevascularizationAdministration IntravenousINTRAVENOUS THROMBOLYSISthrombolysismedicine.medical_specialtyMEDLINE610 Medicine & healthRevascularizationfunctional outcome; registry; revascularization; stroke; thrombectomy; thrombolysisCLASSIFICATIONfunctional outcomePOOLED ANALYSIS03 medical and health sciencesALTEPLASEFibrinolytic AgentsHumansMETAANALYSISbusiness.industryStatin treatment10040 Clinic for NeurologyIV THROMBOLYSISSYMPTOMATIC INTRACEREBRAL HEMORRHAGE3121 General medicine internal medicine and other clinical medicineIschemic strokeEmergency medicine570 Life sciences; biologyObservational studybusiness030217 neurology & neurosurgeryBMJ open
researchProduct

Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells

2005

HMG-CoA reductase inhibitors (statins) exert pleiotropic physiological effects. Among others they attenuate cellular responses to genotoxic and inflammatory stress. We investigated the effect of lovastatin on the expression level of TNF receptors (TNFR) in primary human endothelial cells (HUVEC). ELISA, FACS and immunocytochemical analyses show that lovastatin selectively increases the cell surface expression of TNFR2 without affecting the expression level of TNFR1. This effect of lovastatin is independent from inhibition of cell-cycle progression since cells both in G1- and G2-phase showed elevated levels of TNFR2 after lovastatin treatment. To analyze the physiological relevance of lovast…

medicine.medical_treatmentCellBiologyDownregulation and upregulationE-selectinpolycyclic compoundsGeneticsmedicineHumansReceptors Tumor Necrosis Factor Type IILovastatinReceptorCells CulturedCell adhesion moleculeCell CycleEndothelial Cellsnutritional and metabolic diseasesGeneral MedicineFlow CytometryUp-RegulationCell biologymedicine.anatomical_structureCytokineReceptors Tumor Necrosis Factor Type ICancer researchbiology.proteinlipids (amino acids peptides and proteins)Tumor necrosis factor alphaLovastatinE-Selectinmedicine.drugInternational Journal of Molecular Medicine
researchProduct

The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7.

2018

Chloride intracellular channel 1 (CLIC1) is highly expressed and secreted by human glioblastoma cells and cell lines such as U87, initiating cell migration and tumor growth. Here, we examined whether CLIC1 could be transferred to human primary microvascular endothelial cells (HMEC). We previously reported that the oncogenic microRNA, miR-5096, increased the release of extracellular vesicles (EVs) by which it increased its own transfer from U87 to surrounding cells. Thus, we also examined its effect on the CLIC1 transfer. In homotypic cultures, miR-5096 did not increase the expression of CLIC1 in U87 nor in HMEC. However, the endothelial CLIC1 level increased after exposure to EVs released b…

microRNAtransient receptor potential melastatinglioblastomaexosomechloride intracellular channelResearch PaperOncotarget
researchProduct